Please assess the completion status of the following clinical trial:

Trial Title: BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have reached scheduled end of study in BENEFIT, either by developing CDMS or by completing 24 months~Exclusion Criteria:~* No participation in the initial BENEFIT study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: f

Study Arms:
- Initial IFNB-1b (Interferon beta-1b) (Type: EXPERIMENTAL): Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
- Initial Placebo (Type: EXPERIMENTAL): Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)

Based on this trial design, predict the completion outcome and termination type (if applicable).